179 related articles for article (PubMed ID: 33269655)
21. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
22. Complete disappearance of pulmonary rheumatoid nodules after long term rituximab treatment: case report.
Frade-Sosa B; Azuaga AB; Ruiz-Esquide V; Gómez-Puerta JA; Sanmarti R
Rheumatol Int; 2023 Mar; 43(3):533-536. PubMed ID: 36318308
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary rheumatoid nodules in an etanercept-treated patient.
Hübscher O; Re R; Iotti R
Arthritis Rheum; 2003 Jul; 48(7):2077-8. PubMed ID: 12847707
[No Abstract] [Full Text] [Related]
24. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
26. A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
Park SK; Lee MY; Jang EJ; Kim HL; Ha DM; Lee EK
Clin Exp Rheumatol; 2017; 35(4):689-699. PubMed ID: 28079510
[TBL] [Abstract][Full Text] [Related]
27. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
28. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
[TBL] [Abstract][Full Text] [Related]
29. Occurrence of pulmonary rheumatoid nodules following biological therapies.
Kovács A; Baksay B; Cserenyecz A; Molnár K; Takács M; Szekanecz Z
Clin Rheumatol; 2015 Sep; 34(9):1639-42. PubMed ID: 25267563
[TBL] [Abstract][Full Text] [Related]
30. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Tanaka Y
J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
[TBL] [Abstract][Full Text] [Related]
31. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
32. Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review.
Mihevc M; Koren Krajnc M; Bombek Ihan M; Holc I
Ann Clin Microbiol Antimicrob; 2021 Apr; 20(1):22. PubMed ID: 33827581
[TBL] [Abstract][Full Text] [Related]
33. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
34. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
[TBL] [Abstract][Full Text] [Related]
35. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
36. [Tofacitinib].
Döker S; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
[TBL] [Abstract][Full Text] [Related]
37. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Schulze-Koops H; Strand V; Nduaka C; DeMasi R; Wallenstein G; Kwok K; Wang L
Rheumatology (Oxford); 2017 Jan; 56(1):46-57. PubMed ID: 28028154
[TBL] [Abstract][Full Text] [Related]
38. JAK inhibitors: A broadening approach in rheumatoid arthritis.
Lam S
Drugs Today (Barc); 2016 Aug; 52(8):467-469. PubMed ID: 27722215
[TBL] [Abstract][Full Text] [Related]
39. IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis.
Itoh I; Kasuno K; Yamamoto C; Takahashi N; Shimizu H; Ojima T; Hayashi S; Kimura H; Iwano M
Intern Med; 2020 Mar; 59(6):817-821. PubMed ID: 31813912
[TBL] [Abstract][Full Text] [Related]
40. A patient with urinary tract tuberculosis during treatment with etanercept.
Shibata S; Shono E; Nishimagi E; Yamaura K
Am J Case Rep; 2015 Jun; 16():341-6. PubMed ID: 26040918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]